For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and obesity, the clinical path is fraught with complexity. These patients face a “dual burden”—progressive liver disease compounded by severe…

For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and obesity, the clinical path is fraught with complexity. These patients face a “dual burden”—progressive liver disease compounded by severe…